It rests on estimates provided by sites during feasibility, by sites that wanted to be selected for the study. That is not dishonesty, it is a predictable response to how feasibility works, and it makes the bias systematic rather than random. Which means it is measurable: your own completed studies contain the ratio of estimated to actual enrollment, by site, by country, by therapeutic area. Almost nobody applies it, because applying it means telling a site its number is not credible.
We build the analytics layer for clinical trial execution: CTMS, EDC, eTMF, IRT and vendor operational data integrated into study and portfolio views, enrollment forecasting that accounts for known bias, site performance measured on what sites control, startup analysed as a set of queues rather than a duration, and operational risk indicators a central team will actually act on. Your clinical operations, monitoring and medical functions make the decisions. We make sure they are looking at something true.
Clinical operations reporting is built on CTMS and adjacent operational systems, and those systems hold values because somebody entered them. A site activation date is the date a person typed, which may be the date the activity happened or the date somebody got round to recording it. A monitoring visit report exists when it was uploaded. A deviation appears when it was logged. None of this is unusual or improper, and all of it means the data describes administrative activity as much as study activity.
The consequence is specific and awkward. The people with least time to maintain operational records are at the busiest sites, and the busiest sites are frequently the ones enrolling well. So the data is missing, or late, in a way that correlates with performance, which is the one pattern that makes a metric misleading rather than merely noisy. A site that looks slow on data entry may be fast on enrollment, and a site with impeccable CTMS hygiene may have very little to record. Operational analytics that does not account for latency and completeness as properties of its own data will rank sites partly on their administrative capacity.
Enrollment forecasts inherit feasibility optimism
The bias is systematic, measurable from your own history, and almost never applied.
Operational data is late in a way that correlates with performance
The busiest sites have the least time to update the system you are measuring them with.
CTMS and EDC disagree and both are right
They record different events on different schedules and get reconciled by hand.
Startup is reported as a duration
When it is a set of queues, and the average hides where the waiting actually is.
Every study defined its KPIs differently
So portfolio roll-up is arithmetic on inconsistent units.
Risk indicators report what monitors already knew
Because the signals are within-site rather than cross-site comparisons.
The dashboard is green and the milestone still slips
Because status is self-reported by the person accountable for it.
Reporting is assembled manually every month
And by the time it is assembled, the decision window has moved.
Standardization comes third because it is the step that decides whether portfolio reporting is possible at all. A study-level dashboard can tolerate local definitions. The moment you aggregate across studies, every definitional difference becomes an arithmetic error nobody can see.
Step 1
Assess the decisions and the data behind them
Step 2
Integrate CTMS, EDC, eTMF, IRT and vendor sources
Step 3
Standardize the operational definitions across studies
Step 4
Analyze with the bias and the gaps stated
Step 5
Visualize for the person making the decision
Step 6
Automate the assembly and the exception detection
Step 7
Monitor operational risk with cross-site comparison
Step 8
Optimize against measured outcomes
Operational analytics and clinical data management are connected and are not interchangeable, and the distinction is worth stating because the two get bought from the same budget. This page is execution performance: enrollment, activation, milestones, sites, resources, portfolio. The quality, cleaning, reconciliation and lock readiness of the trial dataset itself is clinical data management, it belongs to your clinical data and medical functions, and it is covered separately in our Clinical Trial Data Solutions work.
Where is the study
Study performance dashboards across enrollment, activation, data flow and milestones
Trial milestone monitoring against plan, with slippage attributed to a cause
Patient recruitment and retention tracking, including screen failure and discontinuation patterns
Site activation and study startup analytics broken into queues rather than durations
Portfolio reporting across studies, on definitions that were reconciled deliberately
Recruitment channel analysis measuring channels on randomised subjects, not referrals
Where is it going
Enrollment forecasting corrected against your historical estimate-to-actual distribution
Scenario modelling for activation and enrollment, with the assumptions named
Timeline forecasting that distinguishes forecast from committed plan
Forecast accuracy monitoring against the forecast you actually issued
Resource and capacity planning tied to forecast enrollment rather than to plan
What needs attention
Site performance analytics on metrics sites control, adjusted for population and design
Risk-based monitoring analytics built on cross-site comparison
Operational risk indicators with thresholds set against your own distributions
Protocol deviation reporting with pattern detection across sites
Exception and escalation routing so a signal reaches an owner rather than a report
CRO and vendor performance scorecards: contracted versus actual milestones and delivery timeliness
Monitoring workload and staffing capacity analytics, including workload forecast and allocation scenarios
How it runs
Automated assembly of study and portfolio reporting, replacing manual consolidation
Data latency and completeness surfaced alongside every metric
Standardized operational KPI definitions with documented study-level mappings
Sponsor and study access separation enforced in the model for CRO environments
Predictive insight where the history supports it, with limits stated plainly
Operational analytics is worth building where a decision recurs and is currently made from a manually assembled file. The value is rarely a new capability. It is the same decision made earlier, from numbers the next level up does not dispute.
| Context | The recurring decision | What the analytics has to get right |
|---|---|---|
| Phase I | Whether the unit can absorb the next cohort on schedule | Short timelines, so latency matters more than breadth |
| Phase II | Whether to expand, adapt or stop | Enrollment and data flow read together, with the design change in view |
| Phase III | Where to add sites, countries or monitoring effort | Forecast corrected for bias, and site metrics that are fair to compare |
| Phase IV and post-approval | Whether long-term follow-up is holding | Retention and contact patterns over years rather than months |
| Study startup | Which queue to push on this week | Queue time separated from activity time, per country and per site |
| Site activation | Which sites to activate next and which to drop | Historical estimate-to-actual at site and investigator level |
| Patient enrollment | Whether the plan is still achievable | A forecast with a range, updated on actuals rather than on hope |
| Protocol deviations | Which patterns need intervention rather than documentation | Cross-site pattern detection, with classification left to quality |
| Monitoring activities | Where to send limited monitoring capacity next | Comparative signals rather than thresholds, and visit history |
| Trial timelines | Whether a committed milestone date still holds | Forecast separated from commitment, with the gap visible |
| Multi-site and multi-country trials | Where regional performance diverges and why | Country-level comparability, since regulatory and care context differ |
| CRO operations | Whether delivery is on plan across a sponsor portfolio | Sponsor separation enforced, and sponsor-specific definitions honoured |
| Portfolio performance | Where to move money, people and attention | Reconciled definitions across studies, with unmappable studies shown apart |
The integration problem here is less about volume than about reconciling systems that each hold a partial, differently timed account of the same study. CTMS says a visit occurred, EDC says data was entered, eTMF says a document exists, IRT says a kit shipped. All four are about the same subject at the same visit and none of them agrees on when.
| System | What it holds | The constraint it brings |
|---|---|---|
| CTMS | Sites, milestones, visits, monitoring activity, deviations | Entered by people, so latency and completeness vary with workload |
| EDC | Collected subject data, queries, entry timestamps | Entry timing is an operational signal, not only a data one |
| eTMF | Essential documents and their status | Completeness is about documents expected, not documents present |
| IRT | Randomisation, kit assignment, supply and resupply | Treatment-revealing, so operational use needs careful aggregation |
| eCOA and ePRO | Patient-reported data and device compliance | Compliance patterns are a retention signal before they are a data one |
| Recruitment platforms | Referral, pre-screening and campaign activity | Referral volume is not enrollment, so channels are judged on randomisations |
| Finance and resourcing | Study spend, effort, vendor cost | Different calendars and cost definitions from the operational systems |
| Vendor operational feeds | Laboratory, imaging and other delivery status | Each on its own schedule and format, like external data generally |
Most clinical operations reporting sits outside the regulated record, and some of it does not. Deviation documentation, monitoring records and TMF content can form part of what an inspection examines. Which systems and reports are in scope, how they are classified and what validation applies are determined by your quality, regulatory and clinical functions. Our role is to build so their determination is enforceable.
Frameworks where they apply
- ICH E6 Good Clinical Practice principles for the conduct of clinical research
- GxP and GAMP 5 where a system supports a regulated activity
- FDA 21 CFR Part 11 and EU Annex 11 for electronic records and signatures where applicable
- Intended use assessed per report and system, not assumed for the estate
Privacy
- HIPAA where protected health information is processed
- GDPR and equivalent regimes, including personal data about site and investigator staff
- Subject-level operational data minimised to what the reporting actually needs
- Investigator and site staff performance data treated as personal data about named people
Access
- Role-based access resolved per user at query time rather than per report
- Sponsor and study separation enforced in the model for CRO and multi-sponsor environments
- Blinding-aware aggregation, so operational views cannot reconstruct assignment
- Export and sharing rights treated as part of the access model, because an export leaves it
Integrity
- Lineage from a reported operational figure back to the system and extract it came from
- Audit trail over access, metric definition changes and report releases
- Data latency and completeness recorded, so a figure can be read as of a date
- Controlled change for definitions and reports that feed oversight or inspection
A study behind plan on enrollment has one symptom and several possible causes, and they require entirely different responses. Reporting the variance without decomposing it produces a monthly meeting in which everybody advocates the intervention they prefer.
| Cause | What the data shows | What it calls for |
|---|---|---|
| Fewer sites active than planned | Activation curve behind plan, enrollment per active site on target | Startup queue intervention, not recruitment spend |
| Sites active but not enrolling | Activation on plan, many sites at or near zero | Site-level engagement, and a look at your feasibility process |
| Enrolling slower per site | All sites below expected rate, fairly uniformly | Protocol or eligibility review, since this is usually design |
| Higher screen failure | Screening on plan, randomisation behind | Eligibility criteria and pre-screening, not more referrals |
| Higher discontinuation | Randomisation on plan, evaluable numbers falling | Retention, burden and visit schedule review |
| Plan was never achievable | Uncorrected feasibility estimates underpinned the plan | Re-forecast with historical correction, and reset expectations |
Clinical operations analytics gets measured on dashboards delivered and reporting effort saved. The outcome that matters higher up is whether committed timelines became more predictable, and whether problems surfaced early enough to be worth surfacing.
| Outcome | How to tell |
|---|---|
| Trial visibility improved | The weekly operational decision is made from one view, not an assembled file |
| Startup and activation accelerated | The binding queue was identified, shortened, and the change is visible in the data |
| Enrollment more predictable | Forecasts carry ranges, are corrected for historical bias, and error is trending down |
| Risks found earlier | Comparative signals are worked by a named owner rather than muted |
| Resources better allocated | Monitoring and site effort follow the signal rather than the schedule |
| Reporting effort reduced | Monthly consolidation is automatic and the output is trusted |
| Oversight strengthened | Portfolio views rest on reconciled definitions, with exceptions shown rather than hidden |
We work with pharmaceutical, biotechnology and CRO organizations on clinical operations analytics: CTMS, EDC, eTMF and IRT data integrated with latency visible, milestone definitions reconciled across studies, enrollment forecasting corrected against your own history, startup measured as queues, and comparative risk signals that reach an owner. Your clinical operations, monitoring and medical functions make the decisions.
CaliberFocus builds clinical operations analytics for pharmaceutical, biotechnology and CRO organizations on CTMS, EDC, eTMF and IRT data. We reconcile milestone definitions across studies, keep data latency and completeness visible, correct enrollment forecasts against your own historical estimate-to-actual ratios, measure startup as queues, and route comparative risk signals to an owner.
- Enrollment forecasts corrected for your own feasibility bias
- Startup measured as queues rather than a single duration
- Site benchmarks built on what sites actually control
- Sponsor and blinding separation enforced in the model
Security & Compliance
